Chi-Ping  Day, Ph.D.

Chi-Ping Day, Ph.D.

  • Center for Cancer Research
  • National Cancer Institute


The goal of Dr. Day's research is to identify driving factors of progression and therapeutic response in cancer by integrative modeling approach, especially using genetically engineered mouse models and computational models, a "reiterate (real) mouse-to-(computer) mouse" strategy.

Areas of Expertise

1) cancer modeling 2) metastatic melanoma 3) preclinical study of immunotherapy


Selected Key Publications

Multimodel preclinical platform predicts clinical response of melanoma to immunotherapy

Pérez-Guijarro E, Yang HH, Araya RE, El Meskini R, Michael HT, Vodnala SK, Marie KL, Smith C, Chin S, Lam KC, Thorkelsson A, Iacovelli AJ, Kulaga A, Fon A, Michalowski AM, Hugo W, Lo RS, Restifo NP, Sharan SK, Van Dyke T, Goldszmid RS, Weaver Ohler Z, Lee MP, Day CP, Merlino G.
Nature Medicine. 26(5): 781-791, 2020. [ Journal Article ]

Melanoblast transcriptome analysis reveals novel pathways promoting melanoma metastasis

Marie KL, Sassano A, Yang HH, Michalowski AM, Michael HT, Guo T, Tsai YC, Weissman AM, Lee MP, Jenkins LM, Zaidi MR, Pérez-Guijarro E, Day CP, Arnheiter H, Davis S, Meltzer PS, Merlino G, Mishra PJ.
Nature Communications. 11(1): 333, 2020. [ Journal Article ]

Preclinical Mouse Cancer Models: A Maze of Opportunities and Challenges

Day CP, Merlino G, Van Dyke T.
Cell. 163(1): 39-53, 2015. [ Journal Article ]

"Glowing head" mice: a genetic tool enabling reliable preclinical image-based evaluation of cancers in immunocompetent allografts

Day CP, Carter J, Weaver Ohler Z, Bonomi C, El Meskini R, Martin P, Graff-Cherry C, Feigenbaum L, Tüting T, Van Dyke T, Hollingshead M, Merlino G.
PLoS One. 9(11): e109956, 2014. [ Journal Article ]

Lentivirus-mediated bifunctional cell labeling for in vivo melanoma study

Day CP, Carter J, Bonomi C, Esposito D, Crise B, Ortiz-Conde B, Hollingshead M, Merlino G.
Pigment Cell Melanoma Res. 22(3): 283-95, 2009. [ Journal Article ]


Mouse models and patient data suggest potential biomarker for immunotherapy response in melanoma

CCR News
April 13, 2020

Immune checkpoint inhibitors are an effective treatment for about a third of patients with metastatic melanoma. Now, mouse models and patient data suggest these cancers are more likely to respond to immunotherapy if their cells resemble fully developed melanocytes rather than less mature precursor cells. Read more...

"Glowing Head" Mice: A Bright Idea to Improve Cancer Models

By Peter Kelmenson, Technical Information Scientist, The Jackson Laboratory eNews
January 19, 2016

Immune-deficient mice engrafted with primary human tumors or cell lines have long been the traditional preclinical models for evaluating candidate cancer drugs.  This strategy, while useful for understanding some key aspects of tumor cell behavior, has had only limited success in predicting the efficacy of promising therapeutic candidates clinically. Read more...

Glowing Mice with Working Immune Systems Make for Better Cancer Models Say Scientists

By Anthony King, BioPharma Reporter
June 18, 2015

Molecules like green fluorescent protein (GFP) and luciferase are much used for tumours inside mouse models. Engineered into tumour cells, these light-emitting markers can be detected by a camera and allow tumour progress to be tracked and quantified.  Read more...

New Breed of Mice May Improve Accuracy for Preclinical Testing of Cancer Drugs

Frederick National Laboratory for Cancer Research
May 6, 2015

A new breed of lab animals, dubbed “glowing head mice,” may do a better job than conventional mice in predicting the success of experimental cancer drugs—while also helping to meet an urgent need for more realistic preclinical animal models. Read more...